Shangrao has a world -class dual academician: Han Zhongchao

It is known as the reputation of "superior to rich and ecological capital". After thousands of years of rise and fall, it contains deep cultural heritage. Since ancient times to the present, people and famous scholars have led their leaders in their respective fields, such as Wang Wenjing, chairman of UFIDA, Cheng Wei, founder of Didi Chuxing, and Yang Longzhong, former vice president of BYD, directly or indirectly promoted the development of their respective industries. In addition, Shangrao also appeared in the world -class academician of the world -class doubles -Han Zhongchao, a world -class two -level academician in the field of biotechnology.

Academician Han Zhongchao

Focus on stem cell research for life battery life

It is understood that Academician Han Zhongchao has been devoted to the field of biotechnology for decades, focusing on stem cell research. In the field of umbilical cord, placenta stem cells, innovation of stem cell technology, and research on the transformation of stem cell technology industry and clinical application transformation:

Academician Han Zhongzhao found that blood stem cells can differentiate vascularization and create new technologies in the internationally the first internationally therapy for ischemic vascular disease. And in 2003, the successful application of blood stem cells in the world was successful in the treatment of poisoning lower limb ischemic diseases, which opened a new path for the effective treatment of ischemic vascular disease;

In addition, Academician Han Zhongchao has long been engaged in the industrial transformation and clinical application of stem cell regeneration medical technology. After a lot of thanks to the basic research of Baosheng medicine, the three generations of perinatal stem cell technology innovation has been led. Technical platform.

At the same time, Academician Han Zhongchao led the research team to carry out the study of severe lower limb ischemic diseases such as arteriosclerosis and diabetic foot for the first time on the basis of a large number of experimental research. , Avoid the pain of amputation. Was widespread concern at home and abroad.

Academician Han Zhongchao has been engaged in research on stem cell technology. He has edited and edited 8 monographs in English and 10 Chinese monographs. He has published more than 700 academic papers, including more than 270 articles in international SCI magazines such as Lancet and Blood. More than 60 invention patents have been applied for, and 30 domestic and foreign science and technology awards have been won. It is a well -deserved leader in the field of stem cell technology.

Elected by the French Academy of France, Academician received high international authorities

In 2006, Han Zhongchao was elected as an academician of the French Academy of Medical Sciences because of his outstanding achievements in stem cell foundation and clinical research. In 2014, Academician Han Zhongchao was elected academician of the French Academy of Technology in France. The Chinese scholar of the Academy of Sciences is also the only Chinese scholar in the field of biotechnology.

The French Academy of Medical Sciences is the highest honor institution in the French medical community. It has strict selection procedures and quota restrictions on academicians. There are 60 foreign academicians. They are selected once every two years according to vacancies. The influence of technical work in Europe and internationally. The reason why Academician Han Zhongchao was able to be elected as a foreign academician was inseparable from his great contribution in the field of biotechnology.

Academician Han Zhongchao enjoys high evaluation internationally. He is described by international scholars to be "stem cells" and a well -deserved leader in the field of biotechnology research. The many research results of the top of the Han Zhong Chaoyuan, including Professor Gluckman, who are known as the "mother of transplant," expressed their hope to cooperate with Academician Han Zhongchao.

Establish a leading position in China's stem cell field to win national awards

It is reported that during the 1990s, Academician Han Zhongchao, who had been hired by the Seventh University of Paris, abandoned the excellent treatment abroad, resolutely chose to return to China to continue the study of stem cells, and was hired as the Chinese Academy of Medical Sciences China Academy of Medical University. (Institute of Hematology) Dean), successively undertakes and participated in the national 863 project, 973 project, the national climbing plan, the National Natural Science Foundation of China, and the National Family Planning Commission's "Industrialization Base of Stem Cell Engineering Products" to engage in technical industrialization demonstration project projects, etc. More than 20 research and development projects.

Due to Academician Han Zhongchao's pioneering work in the field of umbilical cord and placenta stem cells, China has established the leading position of the world in the world in one fell swoop.

Discovering the cause of stem cells to seek the well -being of the people

In 2007, Academician Han Zhongchao was in the original intention of "developing stem cell drugs and serving the social products that can be used for the society and providing the common people." Han Family Union Biotechnology Co., Ltd. was established in Beijing, which is committed to promoting the industrialization of stem cell research results.

After more than ten years of hard work, under the leadership of Academician Han Zhongchao, the Han United Group has accumulated rich experience in the fields of stem cell storage, stem cell drugs, and stem cell anti -aging. Nearly 20 subsidiaries such as Beijing, Guangdong, Tianjin, Zhejiang, and Jiangxi have been established. With cell therapy and regeneration medical technology as the core, focusing on the innovation and development of the cell technology industry. The four major industrial sectors of Hanli Biological, Hanshi Pharmaceutical, Hanshi Medicine, and Henuo Shenzhou (Han's Great Health) are designed to create a complete closed -loop of regenerative medicine.

Up to now, the Han United Group has developed more than 10 new stem cells and five indications approved by IND. It has entered the clinical trial stage. Essence

- END -